

ZIOPHARM ONCOLOGY INC
Form SC 13G/A
February 10, 2011
UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

SCHEDULE 13G

(Amendment No. 2)

UNDER THE SECURITIES EXCHANGE ACT OF 1934

ZIOPHARM Oncology, Inc.
(Name of Issuer)

Common Stock, \$.001 par value
(Title of Class of Securities)

98973P101
(CUSIP Number)

December 31, 2010
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

1 The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 98973P101
13G

Page 2 of 11 Pages

1. NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
ProQuest Investments III, L.P. 20-0992411

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP**

(a)	o
(b)	x

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware

5. SOLE VOTING POWER	-0-
6. SHARED VOTING POWER	1,737,404*
7. SOLE DISPOSITIVE POWER	-0-
8. SHARED DISPOSITIVE POWER	1,737,404*

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,737,404*

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES** o

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
3.5%

12. TYPE OF REPORTING PERSON**
PN
** SEE INSTRUCTIONS BEFORE FILLING OUT

*Includes 438,807 shares subject to currently exercisable warrants..

CUSIP No. 98973P101
13G

Page 3 of 11 Pages

1. NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
ProQuest Associates III LLC20-0992451

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP**
 - (a)
 - (b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware

5. SOLE VOTING POWER	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5. SOLE VOTING POWER -0-
	6. SHARED VOTING POWER 1,737,404*
	7. SOLE DISPOSITIVE POWER -0-
	8. SHARED DISPOSITIVE POWER 1,737,404*

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,737,404*

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES**

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
3.5%

12. TYPE OF REPORTING PERSON**
OO
** SEE INSTRUCTIONS BEFORE FILLING OUT

*Includes 438,807 shares subject to currently exercisable warrants..

CUSIP No. 98973P101
13G

Page 5 of 11 Pages

1. NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Alain Schreiber
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP**

(a)	o
(b)	x
3. SEC USE ONLY
4. CITIZENSHIP OR PLACE OF ORGANIZATION
United States Resident Alien
5. SOLE VOTING POWER
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH -0-
6. SHARED VOTING POWER
1,737,404*
7. SOLE DISPOSITIVE POWER
-0-
8. SHARED DISPOSITIVE POWER
1,737,404*
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,737,404*
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES**

o

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
3.5%
12. TYPE OF REPORTING PERSON**
IN
** SEE INSTRUCTIONS BEFORE FILLING OUT

*Includes 438,807 shares subject to currently exercisable warrants..

CUSIP No. 98973P101
13G

Page 6 of 11 Pages

Item 1(a). Name of Issuer.

ZIOPHARM Oncology, Inc. (the "Company").

Item 1(b). Address of Issuer's Principal Executive Offices.

The Company's principal executive offices are located at 1180 Avenue of the Americas, 19th Floor, New York, NY 10036.

Items 2(a). Name of Person Filing.

This statement is filed on behalf of the following persons with respect to shares of common stock of the Company and warrants to purchase shares of common stock of the Company purchased by such persons (collectively, the "Shares") in connection with a private placement of the Company's securities:

- (i) ProQuest Investments III, L.P., a Delaware limited partnership ("Investments III"), with respect to Shares beneficially owned by it;
- (ii) ProQuest Associates III LLC, a Delaware limited liability company ("Associates III"), as General Partner of Investments III, with respect to Shares beneficially owned by Investments III;
- (iii) Jay Moorin, an individual and a member of Associates III ("Moorin"), with respect to Shares beneficially owned by Investments III; and
- (iv) Alain Schreiber, an individual and a member of Associates III ("Schreiber"), with respect to Shares beneficially owned by Investments III.

The foregoing persons are hereinafter are referred to collectively as the "Reporting Persons." Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

Item 2(b). Address of Principal Business Office or, if None, Residence.

The address of the principal business office of each of the Reporting Persons is 90 Nassau Street, 5th Floor, Princeton, NJ 08542.

Item 2(c). Citizenship.

Mr. Moorin is a United States citizen. Mr. Schreiber is a United States resident alien. Investments III is a Delaware limited partnership organized under the laws of the State of Delaware. Associates III is a Delaware limited liability company organized under the laws of the State of Delaware.

Item 2(d). Title of Class of Securities.

Common stock, par value \$0.001 per share.

CUSIP No. 98973P101
13G

Page 7 of 11 Pages

Item 2(e).

CUSIP Number.

98973P101

Item 3.

If this statement is filed pursuant to Rules 13d-1(b) or 13d- 2(b) or (c), check whether the person filing is a:

- (a) Broker or dealer registered under Section 15 of the Act,
- (b) Bank as defined in Section 3(a)(6) of the Act,
- (c) Insurance Company as defined in Section 3(a)(19) of the Act,
- (d) Investment Company registered under Section 8 of the Investment Company Act of 1940,
- (e) Investment Adviser in accordance with Rule 13d-1 (b)(1)(ii)(E),
- (f) Employee Benefit Plan or Endowment Fund in accordance with 13d-1 (b)(1)(ii)(F),
- (g) Parent Holding Company or control person in accordance with Rule 13d-1 (b)(1)(ii)(G),
- (h) Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
- (i) Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940,
- (j) A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
- (k) Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: _____

Item 4.

Ownership.

The percentages used herein are calculated based upon 48,557,678 shares issued and outstanding, as of November 1, 2010, based upon the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2010, filed with the SEC on November 4, 2010. As of the close of business on December 31, 2010, the Reporting Persons beneficially owned shares of the Company's common stock in the amounts and percentages listed below:

A. ProQuest Investments III, L.P.

CUSIP No. 98973P101
13G

Page 8 of 11 Pages

- (a) Amount beneficially owned: 1,737,404
 - (b) Percent of class: 3.5%
 - (c)
 - (i) Sole power to vote or direct the vote: -0-
 - (ii) Shared power to vote or direct the vote: 1,737,404
 - (iii) Sole power to dispose or direct the disposition: -0-
 - (iv) Shared power to dispose or direct the disposition: 1,737,404
 - B. ProQuest Associates III LLC
 - (a) Amount beneficially owned: 1,737,404
 - (b) Percent of class: 3.5%
 - (c)
 - (i) Sole power to vote or direct the vote: -0-
 - (ii) Shared power to vote or direct the vote: 1,737,404
 - (iii) Sole power to dispose or direct the disposition: -0-
 - (iv) Shared power to dispose or direct the disposition: 1,737,404
 - C. Jay Moorin
 - (a) Amount beneficially owned: 1,737,404
 - (b) Percent of class: 3.5%
 - (c)
 - (i) Sole power to vote or direct the vote: -0-
 - (ii) Shared power to vote or direct the vote: 1,737,404
 - (iii) Sole power to dispose or direct the disposition: -0-
 - (iv) Shared power to dispose or direct the disposition: 1,737,404
 - D. Alain Schreiber
 - (a) Amount beneficially owned: 1,737,404
 - (b) Percent of class: 3.5%
 - (c)
 - (i) Sole power to vote or direct the vote: -0-
 - (ii) Shared power to vote or direct the vote: 1,737,404
-

CUSIP No. 98973P101
13G

Page 9 of 11 Pages

(iii) Sole power to dispose or direct the disposition: -0-

(iv) Shared power to dispose or direct the disposition: 1,737,404

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.ý

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

To the knowledge of the Reporting Persons, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, a number of the Shares which represents more than five percent of the number of outstanding shares of the Shares.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

Not Applicable.

Item 8. Identification and Classification of Members of the Group.

Not Applicable.

Item 9. Notice of Dissolution of Group.

Not Applicable.

Item 10. Certifications.

Each of the Reporting Persons hereby makes the following certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

CUSIP No. 98973P101
13G

Page 10 of 11 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

DATED: February 10, 2011

/s/ Pasquale DeAngelis
Pasquale DeAngelis, as a member of ProQuest
Associates III LLC and on behalf of ProQuest
Investments III, L.P.

*
Jay Moorin, individually

*
Alain Schreiber, individually

*By: /s/ Pasquale DeAngelis
Pasquale DeAngelis, Attorney-in-Fact

CUSIP No. 98973P101
13G

Page 11 of 11 Pages

Index Exhibit

SCHEDULE 13G

Exhibit Number	Exhibit Description
99.1	Joint Filing Agreement (previously filed)
99.2	Power of Attorney (previously filed)